Logo

Qiagen's NeuMoDx Multiplex Test Receives the US FDA's EUA and Expands its COVID-19 Portfolio

Share this

Qiagen's NeuMoDx Multiplex Test Receives the US FDA's EUA and Expands its COVID-19 Portfolio

Shots:

  • The US FDA has granted EUA for Qiagen's NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Assay that will help in identifying and differentiate individuals suspected of respiratory viral infection consistent with COVID-19
  • Qiagen launched the multiplex test in the EU in Nov’2020 and will now begin commercialization in the US. The company acquired NeuMoDx in Sept’2020 and the launch of this test strengthens QIAgen’s footprint in PCR and expand its COVID-19 portfolio
  • The 4-plex test utilizes the high-throughput- automated testing capabilities of the NeuMoDx systems- which includes an assay menu for respiratory- blood-borne virus- transplant- and reproductive health disease areas

­ Ref: Qiagen | Image: Qiagen

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions